Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06632236 |
| Title | 5G-EMERALD: Amivantamab in Malignant Brain Tumours (5G-EMERALD) |
| Acronym | 5G-EMERALD |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Institute of Cancer Research, United Kingdom |
| Indications | |
| Therapies | |
| Age Groups: | child | senior | adult |
| Covered Countries | GBR |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Cambridge University Hospitals | NOT_YET_RECRUITING | Cambridge | CB2 0QQ | United Kingdom | Details | |
| The Royal Marsden Hospital - Drug Development Unit | RECRUITING | Sutton | SM2 5PT | United Kingdom | Details |